Cargando…

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis

Rheumatoid arthritis (RA) is a heterogeneous chronic disease. RA patients should start disease modifying anti-rheumatic drugs (DMARDs) therapy immediately after diagnosis. If first-line treatment with conventional synthetic DMARDs does not relieve the disease, biology and targeted synthetic DMARDs a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jing-Wen, Zhang, Wen-Shuang, Lin, Chang-Song, Xu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794839/ https://www.ncbi.nlm.nih.gov/pubmed/36591263 http://dx.doi.org/10.3389/fimmu.2022.1074329

Ejemplares similares

OA20 Combining B cell depletion and JAKi for difficult-to-treat rheumatoid arthritis
por: Lee, Sook Yan, et al.
Publicado: (2023)

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
por: Regierer, Anne Constanze, et al.
Publicado: (2021)

Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up
por: Chen, Jing-Wen, et al.
Publicado: (2022)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
por: Burja, Blaž, et al.
Publicado: (2020)

P15 JAKi of all trades
por: Watkins, Clara, et al.
Publicado: (2023)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
por: Huss, Viking, et al.
Publicado: (2023)

Ferroptosis in Rheumatoid Arthritis: A Potential Therapeutic Strategy
por: Zhao, Ting, et al.
Publicado: (2022)

EULAR definition of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2021)

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
Publicado: (2017)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis
por: Majnik, Judit, et al.
Publicado: (2022)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
por: Grabner, Michael, et al.
Publicado: (2017)

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022)

Targeting matrix metalloproteases: A promising strategy for herbal medicines to treat rheumatoid arthritis
por: Li, Ruo-Lan, et al.
Publicado: (2022)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2022)

Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
por: Watanabe, Ryu, et al.
Publicado: (2022)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
por: Tan, Yvonne, et al.
Publicado: (2022)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Reestablish immune tolerance in rheumatoid arthritis
por: Shuai, Ziqiang, et al.
Publicado: (2022)

Altered Fecal Metabolomics and Potential Biomarkers of Psoriatic Arthritis Differing From Rheumatoid Arthritis
por: Wang, Nan, et al.
Publicado: (2022)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
por: Krasselt, Marco, et al.
Publicado: (2022)

Identification of potential ferroptosis-associated biomarkers in rheumatoid arthritis
por: He, Xu, et al.
Publicado: (2023)

Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis
por: Jiang, Qi, et al.
Publicado: (2022)

Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients
por: Novella-Navarro, Marta, et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

T-Follicular Regulatory Cells: Potential Therapeutic Targets in Rheumatoid Arthritis
por: Ding, Tingting, et al.
Publicado: (2019)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
por: Vinson, D., et al.
Publicado: (2020)

Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis
por: Ross, Christina L., et al.
Publicado: (2019)

Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis
por: Xue, Jing, et al.
Publicado: (2022)

Neutrophil Extracellular Traps Tied to Rheumatoid Arthritis: Points to Ponder
por: Song, Wenpeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hhm6pthe970qaguhdn8v16hnf